CD8A and neoplasm: In their study, only CD8 + TILs were immunohistochemically examined on the tumor and stroma, being stromal CD8 + TILs identified as the strongest predictors of progression-free survival (PFS) and overall survival (OS) on anti-PD-1 therapy [2].